<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131274">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105077</url>
  </required_header>
  <id_info>
    <org_study_id>2014032273</org_study_id>
    <nct_id>NCT02105077</nct_id>
  </id_info>
  <brief_title>Development of a Mass-spectometry Based Method for Detecting Xenon Application in Humans</brief_title>
  <official_title>Development of a Mass-spectometry Based Method for Detecting Xenon Application in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Sports University, Cologne, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish a laboratory method to determine from blood
      samples whether a person has been treated with xenon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The noble gas xenon is used for general anesthesia in clinical routine. Recent reports
      indicate that xenon is also used for increasing performance in high-performance sports. The
      purpose of this study is to establish a method for detecting xenon exposure in humans.

      In patients undergoing surgery with xenon anesthesia as part of routine hospital care, small
      blood samples (3ml) will be taken before anesthesia, during anaesthesia and at 4, 8 and 14
      hours after anesthesia. These blood samples will be analyzed for traces of xenon.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Detection of xenon in patient blood sample by mass spectrometry</measure>
    <time_frame>Immediately before induction of anesthesia</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of xenon in patient blood sample by mass spectrometry</measure>
    <time_frame>During xenon anesthesia</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of xenon in patient blood sample by mass spectrometry</measure>
    <time_frame>4 hours after extubation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of xenon in patient blood sample by mass spectrometry</measure>
    <time_frame>8 hours after extubation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of xenon in patient blood sample by mass spectrometry</measure>
    <time_frame>24 hours after xenon anesthesia</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Xenon</arm_group_label>
    <description>Patients undergoing surgery with xenon-based general anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anesthesia with inhalative application of xenon gas</intervention_name>
    <arm_group_label>Xenon</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole-blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing xenon-based general anesthesia as part of routine care at University
        Hospital Düsseldorf, Germany
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 years and older

          -  Xenon-based anesthesia as part of routine care

        Exclusion Criteria:

          -  Inability to give written informed consent

          -  Known pregnancy

          -  Hemoglobin concentration of less than 12g/dl
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Kienbaum, M.D.</last_name>
    <phone>+492118116332</phone>
    <email>peter.kienbaum@med.uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Thevis, PhD</last_name>
    <phone>+4922149827070</phone>
    <email>m.thevis@biochem.dshs-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie, Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Kienbaum, M.D.</last_name>
      <phone>+4921116332</phone>
    </contact>
    <investigator>
      <last_name>Peter Kienbaum, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maximilian S Schäfer, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Neukirchen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Anästhesiologie</investigator_full_name>
    <investigator_title>Prof. Dr. Peter Kienbaum</investigator_title>
  </responsible_party>
  <keyword>xenon</keyword>
  <keyword>doping</keyword>
  <keyword>anesthesia</keyword>
  <keyword>mass spectrometry</keyword>
  <keyword>surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Xenon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
